Related Experiment Video

Updated: Jul 11, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K

[Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and

E V Shlyakhto1, G T Sukhikh2, V N Serov2

  • 1Almazov National Medical Research Center.

Kardiologiia
|November 16, 2023
PubMed

Insights

Menopausal hormone therapy (MHT) can safely manage symptoms for women with cardiovascular and metabolic diseases. This consensus provides criteria and an algorithm for physicians to prescribe MHT appropriately, improving quality of life.

Area of Science:

  • Endocrinology and Women's Health
  • Cardiovascular Medicine
  • Metabolic Disorders

Context:

  • Menopausal symptoms significantly impact women's careers and family life.
  • Menopausal Hormone Therapy (MHT) is the most effective treatment for these symptoms.
  • Concurrent cardiovascular and metabolic diseases often pose a barrier to MHT prescription due to physician concerns.

Purpose:

  • To analyze existing clinical trial data on MHT safety in women with cardiovascular and metabolic diseases.
  • To establish criteria for the appropriate use of MHT in this patient population.
  • To provide physicians with a practical algorithm for prescribing MHT to menopausal women with comorbidities.

Summary:

  • A consensus review of clinical trial data was conducted to assess MHT safety in women with cardiovascular and metabolic diseases.
  • Criteria were developed to guide the appropriate prescription of MHT, addressing physician concerns about potential harm.
  • The analysis resulted in an accessible algorithm for physicians to safely manage menopausal symptoms with MHT in women with comorbidities.

Impact:

  • Facilitates informed decision-making for prescribing MHT in women with cardiovascular and metabolic diseases.
  • Aims to improve the quality of life for menopausal women by enabling safe and effective symptom management.
  • Reduces physician hesitancy in prescribing MHT by providing clear guidelines and a decision-making tool.

More Related Videos

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

909
A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

15.5K

Related Concept Videos

Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
172
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
343
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
19
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
14
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
97